Trial Profile
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Temozolomide (Primary) ; Valaciclovir (Primary)
- Indications Glioma
- Focus Adverse reactions; First in man; Proof of concept
- 01 Jun 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Oct 2023.
- 30 Mar 2023 According to a Candel Therapeutics media release, the company announced as part of its HGG portfolio prioritization that it plans to continue development of CAN-3110 in recurrent HGG but does not plan to pursue a phase 3 clinical trial of CAN-2409 in HGG during December R&D Day.
- 30 Jan 2023 Planned End Date changed from 30 Apr 2023 to 31 Oct 2023.